Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 135729-61-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of palonosetron during breastfeeding. Until more data become available, palonosetron should be used with caution during breastfeeding. An alternate drug may be preferred.
No information is available on the use of netupitant, which is the other component of the combination product Akynzeo, during breastfeeding. Because netupitant and its metabolites are more than 97% bound to plasma proteins, the amount in milk is likely to be low. Until more data become available, Akynzeo should be used with caution during breastfeeding. An alternate drug may be preferred.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Palonosetron
CAS Registry Number
135729-61-2
Drug Class
Breast Feeding
Lactation
Milk, Human
Antiemetics
Gastrointestinal Agents
Serotonin Antagonists
Serotonin 5-HT3 Receptor Antagonists
Neurokinin-1 Receptor Antagonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.